Navigation Links
Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
Date:6/7/2012

Berlin, Germany, June 7 2012: Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by 2,595,557 per 272 patients over 3 years (95 percentile range -2,983,760 to -2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs.

The Dutch study, which investigated 272 patients with RA starting adalimumab treatment, measured DAS28** HAQ*** and biologic use over three years. A treatment protocol for personalised care was defined in which EULAR**** response and adalimumab serum drug level test results at six months determined whether adalimumab treatment was continued or discontinued, dosing was altered or, in case of non-response, another biological treatment was started. Using a patient level Markov model, outcomes in DAS28, HAQ, and biologic use for the personalised care group were simulated and compared to the observed drug use and disease course.

Charlotte Krieckaert from the Jan van Breemen Research Institute, Reade, The Netherlands and lead author of the study stated: "Governments and health authorities around the world are looking to save money by cutting costs and providing reduced access to more expensive treatments. This study demonstrates that with careful monitoring and testing disease activity at six months, costs for RA treatment can be reduced and treatment effectiveness can actually increase."

In total, 2,562,494 was saved on biological drug costs and testing costs amounted to 10,872, resulting in an average incremental cost-effectiveness ratio (ICER)***** of -707,236 per QALY gained. Personalised care saved costs and was more effective in 77.6% of simulations, but was cost saving and less effective in 22.4%.


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Page: 1

Related medicine news :

1. Personalizing cancer: Creating biomarkers from tumor DNA
2. Personalizing medicine to prevent pandemics
3. Mayo researchers find biomarkers for personalizing radiation cancer treatment
4. Study carried out into biological risks of eating reptiles
5. Biological clock could be a key to better health, longer life
6. New method to grow arteries could lead to biological bypass for heart disease
7. Biologic Joint Reconstruction Using Stem Cells Proven Successful In Patients With Arthritis
8. U of T researchers crack splicing code, solve a mystery underlying biological complexity
9. Adolescent brains biologically wired to engage in risky behavior, study finds
10. Biologics-naive juvenile idiopathic arthritis patients have elevated risk of cancer
11. Length of biological marker associated with risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the ... heels of Thinksport’s award-winning sunscreen they’ve used the same scientific approach to solving ... Countless deodorants flood the aisles that contain harmful chemicals that should be put ...
(Date:4/27/2017)... ... , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including ... , The first new location will open at the corner of 27th and Randolph ... Lights Drive this fall. And the third location is in the process of being ...
(Date:4/26/2017)... ... 2017 , ... Jump Technologies, Inc., an innovative software company ... a round of funding to accelerate its growth strategies. The $3.5 million investment ... a growth equity firm focused on investments in healthcare and technology companies. This ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Vivify Health, the pioneer and market leader of remote ... significant patent for the advancement of healthcare delivery from ... health.  This landmark patent provides the company with broad ... position as the leader in remote care.  ... to apply consumer mobile devices, wireless biometrics, EMR integration ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
Breaking Medicine Technology: